Clinical trial registry record

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 13, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05390840
Last registry update
March 13, 2024
Status
Unknown
Phase
Phase 2
Sponsor
Theratocular Biotek Co.
Enrollment
36
Countries
Thailand
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
36
Population
ALL · 45 Years
Duration
2022-08-09 to 2024-03-01
Intervention
MG-O-1002; Placebo
Comparator
Part 2 (MG-O-1002 or Placebo)
Outcomes measured
Mean change from baseline in central macular thickness over 12 weeks. — up to 12 weeks; Mean change from baseline in Best-Corrected Visual Acuity over 12 weeks — up to 12 weeks; Mean Change from baseline in Visual Field over 12 weeks — up to 12 weeks; Mean change from baseline in total area of Choroidal Neovascularization (CNV) over 12 weeks — up to 12 weeks; The number of patients needing rescue treatment within 12 weeks — up to 12 weeks; The time to rescue treatment for needed patients within 12 weeks — up to 12 weeks; Incidence and severity of ocular and systemic adverse events — up to 12 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON